InvestorsObserver is giving Actinium Pharmaceuticals Inc (ATNM) an Analyst Rating Rank of 79, meaning ATNM is ranked higher by analysts than 79% of stocks. The average projection by analysts for ATNM is $38.333 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Actinium Pharmaceuticals Inc Stock Today?
Actinium Pharmaceuticals Inc (ATNM) stock is lower by -23.6% while the S&P 500 is up 0.11% as of 10:55 AM on Tuesday, Dec 29. ATNM is lower by -$2.53 from the previous closing price of $10.72 on volume of 1,470,501 shares. Over the past year the S&P 500 has gained 16.09% while ATNM is up 20.44%. ATNM lost -$2.59 per share the over the last 12 months.
Click Here to get the full report on Actinium Pharmaceuticals Inc (ATNM) Stock.